IBJNews

New Lilly drug has small sales potential

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.

Lilly won approval Friday from the U.S. Food and Drug Administration for Amyvid, a new imaging agent that could help physicians better diagnose Alzheimer’s disease and other forms of dementia. Amyvid binds to amyloid plaques, which are a telltale sign of Alzheimer’s disease, making them detectable using a PET scan.

Amyvid will sell at a wholesale price of $1,600 per dose, with distributors likely discounting slightly from that price. The cost of the PET scan is on top of that.

Right now, the federal agency that runs the Medicare and Medicaid programs does not reimburse for imaging agents and scans, and neither do many private health insurance plans. That will limit Lilly’s revenue initially, ISI Group analyst Mark Schoenebaum said in a weekend note to investors.

Even if health insurance start paying, there are only about 450,000 Americans diagnosed with Alzheimer’s each year. So Amyvid could at best produce total U.S. sales of $700 million.

Schoenebaum predicted that Lilly might only generate about $200 million in annual U.S. sales, because the training programs doctors must take to be able to read the Amyvid PET scans are cumbersome, in his view, which will limit the number of doctors that use the drug.

If Lilly were to win approval for Amyvid in Europe, Lilly might tack on another $300 million in annual sales, Schoenebaum predicted.

So far, most analysts who follow Lilly have yet to forecast any specific amount of sales for Amyvid. Investors shrugged at the FDA approval in Monday trading, pushing Lilly’s stock down at roughly the same rate the broader markets declined.

But where Amyvid could prove especially useful is in research for a treatment for Alzheimer’s disease. By helping doctors identify which patients have Alzheimer’s and which do not, Amyvid could help focus research efforts to the right set of patients.

Amyvid scans still will be only part of a doctor’s diagnosis, which will still rely mainly on questioning patients to assess their cognitive abilities. But the Amyvid scans can now show the presence or absence of amyloid plaque, which before could not been seen until an autopsy.

So far, no drug has been shown conclusively to slow or reverse progression of the memory-sapping disease. That’s why analysts project that the first effective treatment would be an enormous blockbuster, perhaps achieving sales of $10 billion per year.

Lilly has been trying to launch such a drug. It had one drug, called semagacestat, fail spectacularly in 2010. Another experimental drug, called solanezumab, is in a final-stage clinical trial. Other companies, such as New Jersey-based Merck & Co. Inc. and New York-based Pfizer Inc., also are trying to develop Alzheimer's treatments.

In addition to solanezumab, Lilly has another Alzhimer’s treatment in a Phase 1 clinical trial.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am so impressed that the smoking ban FAILED in Kokomo! I might just move to your Awesome city!

  2. way to much breweries being built in indianapolis. its going to be saturated market, if not already. when is enough, enough??

  3. This house is a reminder of Hamilton County history. Its position near the interstate is significant to remember what Hamilton County was before the SUPERBROKERs, Navients, commercial parks, sprawling vinyl villages, and acres of concrete retail showed up. What's truly Wasteful is not reusing a structure that could still be useful. History isn't confined to parks and books.

  4. To compare Connor Prairie or the Zoo to a random old house is a big ridiculous. If it were any where near the level of significance there wouldn't be a major funding gap. Put a big billboard on I-69 funded by the tourism board for people to come visit this old house, and I doubt there would be any takers, since other than age there is no significance whatsoever. Clearly the tax payers of Fishers don't have a significant interest in this project, so PLEASE DON'T USE OUR VALUABLE MONEY. Government money is finite and needs to be utilized for the most efficient and productive purposes. This is far from that.

  5. I only tried it 2x and didn't think much of it both times. With the new apts plus a couple other of new developments on Guilford, I am surprised it didn't get more business. Plus you have a couple of subdivisions across the street from it. I hope Upland can keep it going. Good beer and food plus a neat environment and outdoor seating.

ADVERTISEMENT